XML 63 R55.htm IDEA: XBRL DOCUMENT
v3.20.1

License agreements - Merus (Details) $ / shares in Units, $ in Thousands, € in Millions, shares in Millions |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Jan. 23, 2017 USD ($) $ / shares | Feb. 28, 2017 USD ($) | Jan. 31, 2017 USD ($) item | Dec. 31, 2016 USD ($) $ / shares shares | Mar. 31, 2020 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2019 EUR (€) | Dec. 31, 2017 USD ($) | Dec. 31, 2019 USD ($)
License agreements |  |  |  |  |  |  |  |  |  |
Long term investments |  |  |  |  | $ 180,993 |  |  |  | $ 133,657 | [1]
Research and development expense |  |  |  |  | 1,085,287 | $ 270,545 |  |  |  |
Unrealized gain (loss) on long term investments |  |  |  |  | (48,132) | 20,989 |  |  |  |
Current assets |  |  |  |  | 1,716,169 |  |  |  | 2,481,488 | [1]
Current liabilities |  |  |  |  | 503,412 |  |  |  | 513,340 | [1]
Merus |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Number of independent programs | item |  |  | 11 |  |  |  |  |  |  |
Number of preclinical discovery programs | item |  |  | 2 |  |  |  |  |  |  |
Number of programs under the resulting products are co-funded for development | item |  |  | 1 |  |  |  |  |  |  |
Associated future global development costs , if elected to co-develop (as a percent) |  |  | 35.00% |  |  |  |  |  |  |
Upfront payment under license agreement |  | $ 120,000 |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 2,300 | 2,600 |  |  |  |
Merus | Accrued and other liabilities |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Accrued and other liabilities |  |  |  |  | 2,200 |  |  |  | 1,600 |
Merus | U.S. |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Profit sharing (as a percent) |  |  | 50.00% |  |  |  |  |  |  |
Percentage of profit (losses) |  |  | 50.00% |  |  |  |  |  |  |
Merus | Minimum |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 6.00% |  |  |  |  |  |  |
Merus | Minimum | U.S. |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 6.00% |  |  |  |  |  |  |
Merus | Minimum | Non-U.S. |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 6.00% |  |  |  |  |  |  |
Merus | Maximum |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Number of additional preclinical discovery programs | item |  |  | 10 |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 10.00% |  |  |  |  |  |  |
Percentage of reverse royalty |  |  | 4.00% |  |  |  |  |  |  |
Merus | Maximum | U.S. |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 10.00% |  |  |  |  |  |  |
Percentage of additional royalties |  |  | 4.00% |  |  |  |  |  |  |
Merus | Maximum | Non-U.S. |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 10.00% |  |  |  |  |  |  |
Merus | Maximum | Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  | $ 100,000 |  |  |  |  |  |  |
Merus | Maximum | Commercialization Milestones |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  | $ 250,000 |  |  |  |  |  |  |
Merus |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Total revenues | € |  |  |  |  |  |  | € 31.1 |  |  |
Net loss | € |  |  |  |  |  |  | € (55.2) |  |  |
Merus | Stock purchase agreement |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares |  |  |  | 3.2 |  |  |  |  |  |
Purchase price of common stock |  |  |  | $ 80,000 |  |  |  |  |  |
Per share price | $ / shares | $ 24.50 |  |  | $ 25.00 |  |  |  |  |  |
Discount for lack of marketability | $ 5,600 |  |  |  |  |  |  |  |  |
Fair value of shares on the issuance date | 72,800 |  |  |  |  |  |  |  |  |
Total consideration paid | $ 80,000 |  |  |  |  |  |  |  |  |
Long term investments |  |  |  |  |  |  |  | $ 72,800 |  |
Research and development expense |  |  |  |  |  |  |  | $ 7,200 |  |
Fair market value of our long term investments |  |  |  |  | $ 38,700 |  |  |  | $ 45,100 |
Ownership percentage (as a percent) |  |  |  |  | 11.00% |  |  |  |  |
Unrealized gain (loss) on long term investments |  |  |  |  | $ (6,300) | $ (2,500) |  |  |  |
[1] | The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.

X
- Definition Represents the percentage of profits and losses shared under the collaboration agreement. + References No definition available. + Details
Name: | incy_CollaborationAgreementProfitSharingPercentage
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly.. + References No definition available. + Details
Name: | incy_FairValueInputsAmountOfDiscountForLackOfMarketability
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the maximum number of independent programs encompassed under the collaboration agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMaximumNumberOfIndependentPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of additional preclinical discovery programs. + References No definition available. + Details
Name: | incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of preclinical immuno-oncology discovery programs. + References No definition available. + Details
Name: | incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of the upfront payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of programs in which the resulting products are co-funded for development. + References No definition available. + Details
Name: | incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. + References No definition available. + Details
Name: | incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of net sales attributable to additional royalties. + References No definition available. + Details
Name: | incy_PercentageOfNetSalesPertainingToAdditionalRoyalties
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of profits (losses). + References No definition available. + Details
Name: | incy_PercentageOfProfitsLosses
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of reverse royalties on sale of future products. + References No definition available. + Details
Name: | incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. + References No definition available. + Details
Name: | incy_PercentageOfRoyaltyRatePayments
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the purchase of common stock under Stock Purchase Agreement. + References No definition available. + Details
Name: | incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
Namespace Prefix: | incy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of the total consideration paid under purchase agreement during the period. + References No definition available. + Details
Name: | incy_TotalConsiderationPaidUnderPurchaseAgreement
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 + Details
Name: | us-gaap_AssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of the entity's equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_EquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of net income (loss) reported by an equity method investment of the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571 + Details
Name: | us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue from sale of product and rendering of service reported by equity method investee. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 + Details
Name: | us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_LiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_LongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |